Insulin efsitora alfa

Insulin efsitora alfa
Clinical data
Other names	LY3209590; LY-3209590
Legal status
Legal status	Investigational;
Identifiers
CAS Number	2131038-11-2;
UNII	OZ465SMQ28;

Insulin efsitora alfa (LY3209590) is a novel insulin analog developed by Eli Lilly for the treatment of diabetes. Its glycemic control and safety were found similar to insulin degludec in a phase II trial.^[1]^[2]^[3]

References

^ Heise, Tim; Chien, Jenny; Beals, John M.; Benson, Charles; Klein, Oliver; Moyers, Julie S.; Haupt, Axel; Pratt, Edward John (2023). "Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes". Diabetes, Obesity and Metabolism. 25 (4): 1080–1090. doi:10.1111/dom.14956. S2CID 255034380.
^ Moyers, Julie S.; Hansen, Ryan J.; Day, Jonathan W.; Dickinson, Craig D.; Zhang, Chen; Ruan, Xiaoping; Ding, Liyun; Brown, Robin M.; Baker, Hana E.; Beals, John M. (2022). "Preclinical Characterization of LY3209590, a Novel Weekly Basal Insulin Fc-Fusion Protein". Journal of Pharmacology and Experimental Therapeutics. 382 (3): 346–355. doi:10.1124/jpet.122.001105. PMID 35840338.
^ Kazda, Christof M.; Bue-Valleskey, Juliana M.; Chien, Jenny; Zhang, Qianyi; Chigutsa, Emmanuel; Landschulz, William; Wullenweber, Paula; Haupt, Axel; Dahl, Dominik (2023). "Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes". Diabetes Care. 46 (5): 1052–1059. doi:10.2337/dc22-2395. PMC 10154655. PMID 36920867.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[1] Heise, Tim; Chien, Jenny; Beals, John M.; Benson, Charles; Klein, Oliver; Moyers, Julie S.; Haupt, Axel; Pratt, Edward John (2023). "Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes". Diabetes, Obesity and Metabolism. 25 (4): 1080–1090. doi:10.1111/dom.14956. S2CID 255034380.

[2] Moyers, Julie S.; Hansen, Ryan J.; Day, Jonathan W.; Dickinson, Craig D.; Zhang, Chen; Ruan, Xiaoping; Ding, Liyun; Brown, Robin M.; Baker, Hana E.; Beals, John M. (2022). "Preclinical Characterization of LY3209590, a Novel Weekly Basal Insulin Fc-Fusion Protein". Journal of Pharmacology and Experimental Therapeutics. 382 (3): 346–355. doi:10.1124/jpet.122.001105. PMID 35840338.

[3] Kazda, Christof M.; Bue-Valleskey, Juliana M.; Chien, Jenny; Zhang, Qianyi; Chigutsa, Emmanuel; Landschulz, William; Wullenweber, Paula; Haupt, Axel; Dahl, Dominik (2023). "Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes". Diabetes Care. 46 (5): 1052–1059. doi:10.2337/dc22-2395. PMC 10154655. PMID 36920867.

[1]

[2]

[3]